ITUB20169937A1 - Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa - Google Patents

Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa

Info

Publication number
ITUB20169937A1
ITUB20169937A1 ITUB2016A009937A ITUB20169937A ITUB20169937A1 IT UB20169937 A1 ITUB20169937 A1 IT UB20169937A1 IT UB2016A009937 A ITUB2016A009937 A IT UB2016A009937A IT UB20169937 A ITUB20169937 A IT UB20169937A IT UB20169937 A1 ITUB20169937 A1 IT UB20169937A1
Authority
IT
Italy
Prior art keywords
pigmental
retinitis
treatment
pharmaceutical formulations
formulations
Prior art date
Application number
ITUB2016A009937A
Other languages
English (en)
Inventor
Rosa Mario De
Original Assignee
Medical And Biotechnological Services In Sigla M B S Srl
Kaleyde Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical And Biotechnological Services In Sigla M B S Srl, Kaleyde Pharmaceuticals Ag filed Critical Medical And Biotechnological Services In Sigla M B S Srl
Priority to ITUB2016A009937A priority Critical patent/ITUB20169937A1/it
Priority to AU2017206626A priority patent/AU2017206626A1/en
Priority to CA3011077A priority patent/CA3011077A1/en
Priority to CN201780006228.3A priority patent/CN108463237A/zh
Priority to RU2018125290A priority patent/RU2018125290A/ru
Priority to KR1020187019687A priority patent/KR20180100574A/ko
Priority to US16/069,102 priority patent/US20180353565A1/en
Priority to JP2018530866A priority patent/JP2019504006A/ja
Priority to EP17702530.1A priority patent/EP3402504A1/en
Priority to PCT/EP2017/050497 priority patent/WO2017121766A1/en
Publication of ITUB20169937A1 publication Critical patent/ITUB20169937A1/it
Priority to ZA2018/04589A priority patent/ZA201804589B/en
Priority to IL260517A priority patent/IL260517B/en
Priority to HK19101750.7A priority patent/HK1259382A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
ITUB2016A009937A 2016-01-12 2016-01-12 Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa ITUB20169937A1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
ITUB2016A009937A ITUB20169937A1 (it) 2016-01-12 2016-01-12 Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
KR1020187019687A KR20180100574A (ko) 2016-01-12 2017-01-11 색소성 망막염의 치료를 위한 약제학적 제제 및 이의 용도
CA3011077A CA3011077A1 (en) 2016-01-12 2017-01-11 Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
CN201780006228.3A CN108463237A (zh) 2016-01-12 2017-01-11 药物制剂及其用于治疗色素性视网膜炎的用途
RU2018125290A RU2018125290A (ru) 2016-01-12 2017-01-11 Фармацевтические композиции и их применение для лечения пигментного ретинита
AU2017206626A AU2017206626A1 (en) 2016-01-12 2017-01-11 Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
US16/069,102 US20180353565A1 (en) 2016-01-12 2017-01-11 Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
JP2018530866A JP2019504006A (ja) 2016-01-12 2017-01-11 網膜色素変性症の治療のための医薬製剤及びその使用
EP17702530.1A EP3402504A1 (en) 2016-01-12 2017-01-11 Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
PCT/EP2017/050497 WO2017121766A1 (en) 2016-01-12 2017-01-11 Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
ZA2018/04589A ZA201804589B (en) 2016-01-12 2018-07-10 Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
IL260517A IL260517B (en) 2016-01-12 2018-07-10 Pharmaceutical preparations and their use for the treatment of colored retinitis
HK19101750.7A HK1259382A1 (zh) 2016-01-12 2019-01-31 藥物製劑及其用於治療色素性視網膜炎的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2016A009937A ITUB20169937A1 (it) 2016-01-12 2016-01-12 Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa

Publications (1)

Publication Number Publication Date
ITUB20169937A1 true ITUB20169937A1 (it) 2017-07-12

Family

ID=55806719

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2016A009937A ITUB20169937A1 (it) 2016-01-12 2016-01-12 Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa

Country Status (13)

Country Link
US (1) US20180353565A1 (it)
EP (1) EP3402504A1 (it)
JP (1) JP2019504006A (it)
KR (1) KR20180100574A (it)
CN (1) CN108463237A (it)
AU (1) AU2017206626A1 (it)
CA (1) CA3011077A1 (it)
HK (1) HK1259382A1 (it)
IL (1) IL260517B (it)
IT (1) ITUB20169937A1 (it)
RU (1) RU2018125290A (it)
WO (1) WO2017121766A1 (it)
ZA (1) ZA201804589B (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202015718A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 視網膜色素變性治療用胜肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017372A1 (en) * 2006-08-09 2008-02-14 Maria Vincenza Carriero Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236157A1 (en) 1995-11-29 1997-06-05 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product
JP4828670B2 (ja) 1996-10-28 2011-11-30 千寿製薬株式会社 眼循環障害改善剤
FR2784898A1 (fr) 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
WO2003007979A1 (en) 2001-07-18 2003-01-30 Board Of Regents, The University Of Texas System An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
JP4953040B2 (ja) 2001-09-19 2012-06-13 株式会社フジモト・コーポレーション アポトーシス抑制剤
CA2615444A1 (en) 2005-07-15 2007-01-25 Donald J. Baker Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2009089399A2 (en) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
WO2009111169A2 (en) 2008-02-29 2009-09-11 Bausch & Lomb Incorporated Compositions comprising pkc-delta modulators and methods for ocular neuroprotection
WO2010005533A2 (en) 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
EP2251028A1 (en) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
JP2012062258A (ja) 2010-09-14 2012-03-29 Oriza Yuka Kk 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤
AU2012249921B2 (en) 2011-04-26 2017-06-08 Biojiva Llc Oxidative retinal diseases
WO2014100361A1 (en) 2012-12-19 2014-06-26 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
US20160193296A1 (en) * 2012-12-19 2016-07-07 Brown University Methods for treatment of microcephaly associated autism disorders
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
EP3331897B1 (en) * 2015-08-05 2021-03-24 Allergan, Inc. Phenyl urea analogs as formyl peptide receptor 1 (fpr1) selective agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017372A1 (en) * 2006-08-09 2008-02-14 Maria Vincenza Carriero Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
K. BIFULCO ET AL: "A Urokinase Receptor-Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting", MOLECULAR CANCER THERAPEUTICS, vol. 12, no. 10, 1 October 2013 (2013-10-01), US, pages 1981 - 1993, XP055284884, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-13-0077 *
M. V. CARRIERO ET AL: "Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis", MOLECULAR CANCER THERAPEUTICS, vol. 8, no. 9, 25 August 2009 (2009-08-25), US, pages 2708 - 2717, XP055284885, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-0174 *
M. V. CARRIERO ET AL: "UPARANT: A Urokinase Receptor-Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency", MOLECULAR CANCER THERAPEUTICS, vol. 13, no. 5, 4 April 2014 (2014-04-04), US, pages 1092 - 1104, XP055284866, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-13-0949 *
MASSIMO DAL MONTE ET AL: "Biochemistry and Molecular Biology Antiangiogenic Effectiveness of the Urokinase Receptor-Derived Peptide UPARANT in a Model of Oxygen-Induced Retinopathy", INVEST OPHTHALMOL VIS SCI, vol. 56, 1 April 2015 (2015-04-01), pages 2392 - 2407, XP055285333, DOI: doi:10.1167/iovs.14-16323 *

Also Published As

Publication number Publication date
ZA201804589B (en) 2019-09-25
US20180353565A1 (en) 2018-12-13
CA3011077A1 (en) 2017-07-20
KR20180100574A (ko) 2018-09-11
EP3402504A1 (en) 2018-11-21
RU2018125290A (ru) 2020-02-13
CN108463237A (zh) 2018-08-28
RU2018125290A3 (it) 2020-06-22
IL260517B (en) 2020-04-30
WO2017121766A1 (en) 2017-07-20
HK1259382A1 (zh) 2019-11-29
JP2019504006A (ja) 2019-02-14
AU2017206626A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
EP3402490A4 (en) THERAPEUTIC USE OF MITOCHONDRIUM AND COMBINED MITOCHONDRY AGENTS
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
BR112016025787A2 (pt) Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
DK3601277T3 (da) Farmaceutisk formulering
EP3497080A4 (en) PHARMACEUTICAL FORMULATIONS AND THEIR USE
DK3454879T3 (da) Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft
IL274868A (en) History of imidazopyridine and their use as medicine
ITUB20169937A1 (it) Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
IT201700111939A1 (it) Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
IT201700038005A1 (it) Dispositivo per la somministrazione di sostanze
IT201800007580A1 (it) Composti 1,3,8-triazaspiro e loro uso come medicamenti
ITUA20163037A1 (it) Formulazioni per uso nel trattamento o prevenzione di disturbi urologici
DK3153163T3 (da) Farmaceutisk forbindelse der omfatter 13 glycerider, formulering og anvendelse deraf